ArticleFrontiers in nutrition2025
Phase angle as a novel indicator of sarcopenic obesity in patients undergoing hemodialysis.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Vicious Cycle of Inflammation: How Obesity, Dialysis Catheters, and NETosis Determine Albumin Levels and Prognosis in Hemodialysis Patients.International journal of molecular sciences · 2026Article
- NRS2002-stratified body composition and laboratory characteristics in hospitalized cancer patients assessed by bioelectrical impedance analysis.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between phase angle (PhA) and sarcopenic obesity (SO) in patients undergoing hemodialysis (HD) has not been well established. Therefore, this study aimed to evaluate the relationship between PhA and SO in patients undergoing HD and to determine the cutoff value of PhA that can predict SO. Methods: We conducted a cross-sectional study of 436 patients undergoing HD. The PhA was measured by bioelectrical impedance analysis. SO was diagnosed according to the revised definition of the Asian Working Group for Sarcopenia combined with obesity based on body fat percentage. The association between PhA and SO was assessed using multinomial logistic regression. The PhA cutoff values for SO were determined using receiver operating characteristic (ROC) curve analysis. Results: Among the participants, 119 (27.3%) had SO. After adjusting for various confounders, PhA was significantly associated with a lower SO risk [odds ratio (OR) = 0.098, 95% confidence interval (CI): 0.048-0.200]. Furthermore, PhA showed a stronger association with SO than with sarcopenia or obesity alone. ROC analysis indicated excellent predictive ability for SO in both sexes (area under the curve (AUC): 0.841 for males, 0.836 for females; cutoff values: 4.49° for males, 4.18° for females). Conclusion: PhA exhibited good accuracy in detecting SO in patients undergoing HD, suggesting its utility as a reliable screening tool for the early identification of at-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.